E Vizza1, G Cutillo1, V Bruno2, I Sperduti3, E Mancini1, E Baiocco1, B Chiofalo1, L Cicchillitti1, C Certelli1, A Zampa1, E Piccione4, G Corrado5. 1. Department of Experimental Clinical Oncology, Gynecologic Oncology Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. 2. Department of Experimental Clinical Oncology, Gynecologic Oncology Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy; Academic Department of Biomedicine and Prevention, Section of Gynecology, Tor Vergata University Hospital, Rome, Italy. Electronic address: valentina.bruno@ifo.gov.it. 3. Scientific Direction, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. 4. Academic Department of Surgical Sciences, Section of Gynecology, Tor Vergata University Hospital, Rome, Italy. 5. Department of Women and Children Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Abstract
INTRODUCTION: Endometrial cancer (EC) known prognostic factors are not sufficient to predict either outcome or recurrence rate/site: to investigate EC recurrence patterns according to ESMO-ESGO-ESTRO risk classes, could be beneficial for a more tailored adjuvant treatment and follow-up schedule. METHODS: 758 women diagnosed with EC, and a 5-years follow-up, were enrolled: they were divided into the ESMO-ESGO-ESTRO risk classes (low LR, intermediate IR, intermediate-high I-HR, and highrisk HR) and surgically treated as recommended, followed by adjuvants therapies when appropriate. RESULTS: Higher recurrence rate (RR) was significantly detected (p < 0,001) in the HR group (40,3%) compared to LR (9,6%), IR (16,7%) and I-HR (17,1%). Recurrences were detected more frequently at distant sites (64%) compared to pelvic (25,3%) and lymph nodes (10,7%) recurrences (p < 0,0001): only in LR group, no differences were detected between local and distant recurrences. 5-Year distant-free (LR 99%, IR 94%,I-HR 86%, HR 88%) and local-free survivals (LR 99%, IR 100%,I-HR 98%, HR 95%) significantly differ between groups (p < 0,0001 and p = 0,003, respectively). Adjuvant therapy modifies RRs only in LR group (p = 0,01). CONCLUSION: To identify biological factors to stratify patients at higher risk of relapse is needed. Distant site relapse could be the main reason of endometrial cancer failure follow-up, independently or in addition to their risk class prognosis.
INTRODUCTION:Endometrial cancer (EC) known prognostic factors are not sufficient to predict either outcome or recurrence rate/site: to investigate EC recurrence patterns according to ESMO-ESGO-ESTRO risk classes, could be beneficial for a more tailored adjuvant treatment and follow-up schedule. METHODS: 758 women diagnosed with EC, and a 5-years follow-up, were enrolled: they were divided into the ESMO-ESGO-ESTRO risk classes (low LR, intermediate IR, intermediate-high I-HR, and highrisk HR) and surgically treated as recommended, followed by adjuvants therapies when appropriate. RESULTS: Higher recurrence rate (RR) was significantly detected (p < 0,001) in the HR group (40,3%) compared to LR (9,6%), IR (16,7%) and I-HR (17,1%). Recurrences were detected more frequently at distant sites (64%) compared to pelvic (25,3%) and lymph nodes (10,7%) recurrences (p < 0,0001): only in LR group, no differences were detected between local and distant recurrences. 5-Year distant-free (LR 99%, IR 94%,I-HR 86%, HR 88%) and local-free survivals (LR 99%, IR 100%,I-HR 98%, HR 95%) significantly differ between groups (p < 0,0001 and p = 0,003, respectively). Adjuvant therapy modifies RRs only in LR group (p = 0,01). CONCLUSION: To identify biological factors to stratify patients at higher risk of relapse is needed. Distant site relapse could be the main reason of endometrial cancer failure follow-up, independently or in addition to their risk class prognosis.
Authors: Laureen P Helweg; Beatrice A Windmöller; Leonie Burghardt; Jonathan Storm; Christine Förster; Nils Wethkamp; Ludwig Wilkens; Barbara Kaltschmidt; Constanze Banz-Jansen; Christian Kaltschmidt Journal: Int J Mol Sci Date: 2022-02-22 Impact factor: 5.923
Authors: Jorge Luis Ramon-Patino; Ignacio Ruz-Caracuel; Victoria Heredia-Soto; Luis Eduardo Garcia de la Calle; Bulat Zagidullin; Yinyin Wang; Alberto Berjon; Alvaro Lopez-Janeiro; Maria Miguel; Javier Escudero; Alejandro Gallego; Beatriz Castelo; Laura Yebenes; Alicia Hernandez; Jaime Feliu; Alberto Pelaez-García; Jing Tang; David Hardisson; Marta Mendiola; Andres Redondo Journal: Cancers (Basel) Date: 2022-02-12 Impact factor: 6.639